|
International Journal of Reproductive BioMedicine
Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences of Yazd
ISSN: 1680-6433 EISSN: 1680-6433
Vol. 18, No. 1, 2020, pp. 41-46
|
Bioline Code: rm20005
Full paper language: English
Document type: Research Article
Document available free of charge
|
|
International Journal of Reproductive BioMedicine, Vol. 18, No. 1, 2020, pp. 41-46
en |
Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: A randomized controlled trial
Ghasemzadeh, Alieh; Faliz, Masumeh Dopour; Farzadi, Laya; Navali, Nazli; Bahramzadeh, Behzad; Fadavi, Arash; Hakimi, Parvin; Tehrani-ghadim, Sepideh; fard, Sedigheh Abdollahi & Hamdi, Kobra
Abstract
Background: Oral progesterone is recommended as an alternative to gonadotropin-releasing
hormone (GnRH) agonists and antagonists to prevent luteinizing hormone
(LH) surge in assisted reproductive technology (ART) cycles. However, there are little
data regarding its use.
Objective: We aimed to compare the effect of oral Utrogestan and Cetrotide (a GnRH
antagonist) on preventing LH surge in ART cycles.
Materials and Methods: In this randomized clinical trial, 100 infertile women
undergoing ART who received recombinant follicle-stimulating hormone (FSH) at 150-225 IU/day were randomly assigned to receive either Utrogestan 100 mg twice a day
(case group) or GnRH antagonist protocol (control group) from cycle day 3 until the
trigger day. Triggering was performed with 10,000 IU hCG) when there were at least
three mature follicles. Viable embryos were cryopreserved for transfer in the next
cycle for both groups. The number of oocytes retrieved and transferred embryos were
compared between groups.
Results: The case group had significantly higher progesterone levels on triggering day,
more follicles of >14 mm with higher maturity, and more oocytes retrieved with a higher
rate of embryos transferred. A small increase in the pregnancy rate was observed in the
case group, with no significant between-group differences. The most important result
was the lack of premature LH surge in either group upon serum LH assessment on the
triggering day.
Conclusion: Utrogestan is an alternative treatment that could reduce the LH surge
rate and increase the ART outcomes including the number of oocytes retrieved and
transferred embryos compared with GnRH agonists and antagonists.
Keywords
In vitro fertilization; Premature luteinization; Utrogestan.
|
|
© Copyright 2020 - Ghasemzadeh et al. Alternative site location: http://www.ijrm.ir
|
|